MARKET

CRVO

CRVO

CervoMed
NASDAQ
1.460
+0.130
+9.77%
After Hours: 1.440 -0.02 -1.37% 19:59 11/20 EST
OPEN
1.530
PREV CLOSE
1.330
HIGH
1.650
LOW
1.401
VOLUME
1.20M
TURNOVER
--
52 WEEK HIGH
10.00
52 WEEK LOW
1.270
MARKET CAP
21.86M
P/E (TTM)
-0.5225
1D
5D
1M
3M
1Y
5Y
1D
CervoMed Inc. Presents 24-Week Interim Biomarker Data from Phase 2a Trial of Neflamapimod
NASDAQ · 3d ago
CervoMed Reports Interim Biomarker Data for Neflamapimod Trial
TipRanks · 4d ago
CervoMed Presents 24-Week Biomarker Data From Participants Enrolled In US Cohort Of Phase 2a Clinical Trial Of Neflamapimod, Oral P38α Inhibitor, In Nonfluent Variant Primary Progressive Aphasia, At CTAD Conference
Benzinga · 4d ago
Weekly Report: what happened at CRVO last week (1109-1113)?
Weekly Report · 4d ago
CervoMed: Buy Rating and $12 Price Target Maintained on Neflamapimod’s Broad Neurological Potential
TipRanks · 11/14 00:25
CervoMed Consensus Price Target Increased by 16.92% to $15.50
NASDAQ · 11/13 01:42
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 11/11 17:05
CervoMed price target lowered to $6 from $7 at Roth Capital
TipRanks · 11/10 16:29
More
About CRVO
CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.

Webull offers CervoMed Inc stock information, including NASDAQ: CRVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRVO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRVO stock methods without spending real money on the virtual paper trading platform.